
Zoetis (ZTS) announced that the U.S. Department of Agriculture, USDA, has licensed Poulvac Procerta HVT-ND-ILT, a vector vaccine for chickens. The license marks an important milestone in Zoetis’ continued investment
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ZTS | Zoetis | 79.11 | -40.26 | -33.73% |
| Name | Price | % Change | |
|---|---|---|---|
| $79.11 | -33.73% |

Zoetis (ZTS) announced that the U.S. Department of Agriculture, USDA, has licensed Poulvac Procerta HVT-ND-ILT, a vector vaccine for chickens. The license marks an important milestone in Zoetis’ continued investment

Zoetis (ZTS) announced that the United States Department of Agriculture, USDA, has licensed Cytopoint Plus for the treatment of allergic dermatitis in dogs. Cytopoint Plus is the first and only

Zoetis (($ZTS)) has held its Q3 earnings call. Read on for the main highlights of the call. Zoetis delivered a mixed third-quarter performance, combining resilient livestock and diagnostics growth with

Stifel raised the firm’s price target on Zoetis (ZTS) to $85 from $80 and keeps a Hold rating on the shares. Zoetis delivered revenue and EPS upside in Q3, but

Reports Q3 revenue $2.4B, consensus $2.3B.”Our third-quarter performance was in line with our expectations. Continued pressure in Companion Animal was partially offset by growth in Livestock and Diagnostics, reflecting the

Consensus $6.26. Narrowed revenue to a range of $9.22B to $9.32B, consensus $9.29B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See

Morgan Stanley lowered the firm’s price target on Zoetis (ZTS) to $82 from $85 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source

UBS raised the firm’s price target on Zoetis (ZTS) to $85 from $80 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate source for

UBS raised the firm’s price target on Zoetis (ZTS) to $85 from $80 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate source for

Zoetis (ZTS) announced that the U.S. FDA has approved Convenia RTU for Dogs for the treatment of susceptible bacterial skin infections in dogs. For many families, administering oral antibiotics daily
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Reiterated | Nov 17, 2026 | ||||
| hold | Reiterated | Nov 9, 2026 | ||||
| hold | Reiterated | Nov 6, 2026 | ||||
| hold | Reiterated | Nov 6, 2026 | ||||
| hold | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 | ||||
| hold | Downgraded | Oct 20, 2026 | ||||
| hold | Initiated | Oct 16, 2026 | ||||
| buy | Reiterated | Oct 16, 2026 | ||||
| hold | Reiterated | Oct 1, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 16, 2027TBA | $32.14B | $1.21 | $2.18B | 2.04 | 13.43 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.